Lametta

Letrozole, the active ingredient in Lametta, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of postmenopausal estrogen receptor‑positive breast cancer, both as adjuvant and advanced‑disease therapy.

GNH USA supplies Lametta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole acts on estrogen‑dependent breast cancer pathways, reducing tumor growth and recurrence. - Postmenopausal estrogen receptor‑positive breast cancer: provides adjuvant therapy to lower risk of disease recurrence. - Advanced hormone‑receptor positive breast cancer: inhibits tumor progression in metastatic settings. - Neoadjuvant breast cancer treatment: helps shrink tumors before surgical removal.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Arthralgia: joint pain or stiffness. - Headache: mild to moderate intensity. - Increased sweating: excessive perspiration.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot migration to lungs. - Severe liver injury: marked elevation of hepatic enzymes. - Bone fracture: increased risk due to lowered estrogen. - Cardiac arrhythmia: rare QT‑interval prolongation.

Before initiating Letrozole therapy, several safety considerations should be reviewed. - Pregnancy contraindication: Category X; avoid use in pregnant women. - Liver function monitoring: assess hepatic enzymes periodically. - Bone health assessment: evaluate risk of osteoporosis or fractures. - Cardiovascular risk evaluation: consider history of thrombosis or heart disease. - Drug interaction review: check concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Letrozole can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP2A6 inhibitors: may raise letrozole plasma levels. - Tamoxifen: concurrent use reduces therapeutic benefit of both agents. - Estrogen replacement therapy: antagonizes letrozole’s mechanism.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect and INR. - Antidiabetic drugs: potential alteration of glucose control. - Certain antidepressants: may enhance central nervous system side effects.